Appendice A

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table A.1 - IGRA and TST sensitivity (5mm and 10mm cut-offs) according to sex, age group, comorbidities (chronic renal failure, oncologic disease, inflammatory disease, HIV, diabetes and COPD), substance abuse (alcohol or drug abuse) and site of disease (pulmonary or extrapulmonary) in patients submitted to both assays (n=727). | | | | | | | | | | | | |
| **Variables** | | **Patients**  **n/N (%)** | **IGRA** | | **TST - 5mm** | | **TST - 10mm** | | **IGRA/TST-5mm** | | **IGRA/TST-10mm** | |
| **Positive**  **(n)** | **Sensitivity**  **% (IC 95%)** | **Positive**  **(n)** | **Sensitivity**  **% (IC 95%)** | **Positive**  **(n)** | **Sensitivity**  **% (IC 95%)** | **Positive**  **(n)** | **Sensitivity**  **% (IC 95%)** | **Positive**  **(n)** | **Sensitivity**  **% (IC 95%)** |
| Total | | 727 | 599 | 82.4  (79.5-84.9) | 615 | 84.6  (82.0-87.2) | 570 | 78.4  (75.4-81.4) | 667 | 91.7  (89.7-93.7) | 659 | 90.6  (88.5-92.8) |
| Sex | Male | 362/727  (49.8) | 304 | 84.0  (79.9-87.4) | 311 | 85.2  (81.6-88.8) | 292 | 91.2  (88.3-94.1) | 334 | 91.0  (88.0-93.9) | 327 | 91.0  (88.0-93.9) |
| Female | 365/727  (50.2) | 295 | 80.8  (76.5-84.5) | 304 | 84.0  (80.2-87.8) | 278 | 92.3  (89.5-95.0) | 333 | 90.3  (87.3-93.4) | 332 | 90.3  (87.3-93.4) |
| Age | ≤15 | 48/727  (6.6) | 37 | 77.1  (63.5-86.7) | 35 | 72.9  (60.3-85.5) | 31 | 85.4  (75.4-95.4) | 41 | 85.4  (75.4-95.4) | 41 | 85.4  (75.4-95.4) |
| 16 – 64 | 523/727  (71.9) | 431 | 82.4  (78.9-85.4) | 458 | 87.6  (84.7-90.4) | 423 | 92.5  (90.3-95.0) | 484 | 91.2  (88.8-93.6) | 477 | 91.2  (88.8-93.6) |
| ≥ 65 | 156/727  (21.5) | 131 | 84.0  (77.4-88.9) | 122 | 78.2  (71.7-84.7) | 116 | 91.0  (86.5-95.5) | 142 | 90.4  (85.8-95.0) | 141 | 90.4  (85.8-95.0) |
| Comorbidities | Chronic renal failure | 5/727  (0.7) | 4 | 80.0  (37.6-96.4) | 3 | 60.0  (14.7-94.7) | 3 | 80.0  (28.4-99.5) | 4 | 80.0  (28.4-99.5) | 4 | 80.0  (28.4-99.5) |
| Oncologic diseases | 36/727  (5.0) | 23 | 63.9  (47.6-77.5) | 23 | 63.9  (48.2-79.6) | 20 | 72.2  (57.6-86.9) | 26 | 69.4  (54.4-84.5) | 25 | 69.4  (54.4-84.5) |
| Inflammatory diseases | 32/727  (4.4) | 20 | 62.5  (45.3-77.1) | 24 | 75.0  (60.0-90.0) | 21 | 75.0  (60.0-90.0) | 24 | 71.9  (56.3-87.5) | 23 | 71.9  (56.3-87.5) |
| HIV infection | 25/632  (3.4) | 18 | 72.0  (52.4-85.7) | 16 | 64.0  (44.5-79.8) | 15 | 76.0  (56.6-88.5) | 19 | 76.0  (56.6-88.5) | 19 | 76.0  (56.6-88.5) |
| Diabetes | 41/727  (5.6) | 32 | 78.0  (63.3-88.0) | 31 | 75.6  (62.5-88.8) | 27 | 80.5  (68.4-92.6) | 33 | 80.5  (68.4-92.6) | 33 | 80.5  (68.4-92.6) |
| COPD | 16/727  (2.2) | 15 | 93.8  (71.7-98.9) | 16 | 100  (79.4-100) | 15 | 100  (79.4-100) | 16 | 100  (79.4-100) | 16 | 100  (79.4-100) |
| Substance abuse | Alcohol abuse | 31/706  (4.3) | 28 | 90.3  (75.1-96.7) | 27 | 87.1  (75.3-98.9) | 25 | 93.5  (78.6-99.2) | 29 | 93.5  (78.6-99.2) | 29 | 93.5  (78.6-99.2) |
| Drug abuse | 32/709  (4.4) | 27 | 84.4  (68.3-93.1) | 31 | 96.9  (83.8-99.9) | 31 | 100  (89.1-100) | 32 | 100  (89.1-100) | 32 | 100  (89.1-100) |
| Site  of  disease | PTB | 343/727  (47.2) | 275 | 80.2  (75.6-84.1) | 292 | 85.1  (81.4-88.9) | 270 | 91.5  (88.6-94.5) | 314 | 90.7  (87.6-93.7) | 311 | 90.7  (87.6-93.7) |
| ETB | 384/727  (52.8) | 324 | 84.4  (80.4-87.7) | 323 | 84.1  (80.5-87.8) | 300 | 91.9  (89.2-94.7) | 353 | 90.6  (87.7-93.5) | 348 | 90.6  (87.7-93.5) |
| PTB = Pulmonary tuberculosis; ETB = Extrapulmonary tuberculosis | | | | | | | | | | | | |

Appendice B

Figure B.1. Number of true positive, false negative and indeterminate results of IGRA by age groups (n=1230).